Trial Profile
A Phase 1 Study of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 May 2023
Price :
$35
*
At a glance
- Drugs DCR PH1 (Primary)
- Indications Primary hyperoxaluria type 1
- Focus Adverse reactions; First in man
- Sponsors Dicerna Pharmaceuticals
- 06 Apr 2022 This trial has been completed in Netherlands, according to European Clinical Trials Database record.
- 10 Aug 2017 Status changed from active, no longer recruiting to discontinued according to a Dicerna Pharmaceuticals media release.
- 11 Oct 2016 Status changed from recruiting to active, no longer recruiting.